These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31401795)

  • 1. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.
    Brandenburg VM; Sinha S; Torregrosa JV; Garg R; Miller S; Canals AZ; Bahr D; Joubert PH; Salcedo C; Carroll KJ; Gold A; Perelló J
    J Nephrol; 2019 Oct; 32(5):811-821. PubMed ID: 31401795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis.
    Sinha S; Gould LJ; Nigwekar SU; Serena TE; Brandenburg V; Moe SM; Aronoff G; Chatoth DK; Hymes JL; Miller S; Padgett C; Carroll KJ; Perelló J; Gold A; Chertow GM
    Clin Kidney J; 2022 Jan; 15(1):136-144. PubMed ID: 35035944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the BWAT-CUA Scale to Assess Wounds in Patients with Calciphylaxis.
    Gould LJ; Serena TE; Sinha S
    Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33924020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.
    Raggi P; Bellasi A; Bushinsky D; Bover J; Rodriguez M; Ketteler M; Sinha S; Salcedo C; Gillotti K; Padgett C; Garg R; Gold A; Perelló J; Chertow GM
    Circulation; 2020 Mar; 141(9):728-739. PubMed ID: 31707860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study.
    Bushinsky DA; Raggi P; Bover J; Ketteler M; Bellasi A; Rodriguez M; Sinha S; Garg R; Perelló J; Gold A; Chertow GM; ;
    Clin J Am Soc Nephrol; 2021 May; 16(5):736-745. PubMed ID: 33835939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.
    Perelló J; Ferrer MD; Del Mar Pérez M; Kaesler N; Brandenburg VM; Behets GJ; D'Haese PC; Garg R; Isern B; Gold A; Wolf M; Salcedo C
    Br J Pharmacol; 2020 Oct; 177(19):4400-4415. PubMed ID: 32557649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.
    Perelló J; Joubert PH; Ferrer MD; Canals AZ; Sinha S; Salcedo C
    Br J Clin Pharmacol; 2018 Dec; 84(12):2867-2876. PubMed ID: 30280390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels.
    Perelló J; Gómez M; Ferrer MD; Rodríguez NY; Salcedo C; Buades JM; Pérez MM; Torregrosa JV; Martín E; Maduell F
    J Nephrol; 2018 Apr; 31(2):287-296. PubMed ID: 29350348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multidisciplinary regenerative treatment and mechanisms for rescuing a severe calciphylaxis patient with human amnion-derived mesenchymal stem cells].
    Wang NN; Qin LJ; Liu K; Xing CY; Zhang J; Xiao YJ; Cui YG; Ning S; Yuan YG; Lu Y; Zhang ZH; Su ZL; Ye XX; Bian AN; Zeng M; Wang Q; Xu FY; Ren WK; Lyu XL; Wang L; Zhao J; Wang ML; Ma X; Liu CP; Wang XQ; Liang NX; Liu JY
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2217-2221. PubMed ID: 35872588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel assay to measure calcification propensity: from laboratory to humans.
    Perez MM; Ferrer MD; Lazo-Rodriguez M; Canals AZ; Banon-Maneus E; Campistol JM; Miller S; Garg R; Gold A; Salcedo C; Perelló J
    Sci Rep; 2020 Oct; 10(1):17578. PubMed ID: 33067536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.
    Salcedo C; Joubert PH; Ferrer MD; Canals AZ; Maduell F; Torregrosa V; Campistol JM; Ojeda R; Perelló J
    Br J Clin Pharmacol; 2019 Apr; 85(4):796-806. PubMed ID: 30632182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SNF472, a novel anti-crystallization agent, inhibits induced calcification in an in vitro model of human aortic valve calcification.
    Zabirnyk A; Ferrer MD; Bogdanova M; Pérez MM; Salcedo C; Kaljusto ML; Kvitting JP; Stensløkken KO; Perelló J; Vaage J
    Vascul Pharmacol; 2019; 122-123():106583. PubMed ID: 31437530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.
    Bellasi A; Raggi P; Bover J; Bushinsky DA; Chertow GM; Ketteler M; Rodriguez M; Sinha S; Salcedo C; Garg R; Gold A; Perelló J
    Clin Kidney J; 2021 Jan; 14(1):366-374. PubMed ID: 33564440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial.
    Raggi P; Bellasi A; Sinha S; Bover J; Rodriguez M; Ketteler M; Bushinsky DA; Garg R; Perelló J; Gold A; Chertow GM
    Kidney Int Rep; 2020 Dec; 5(12):2178-2182. PubMed ID: 33305110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calciphylaxis and nonhealing wounds: the role of the vascular surgeon in a multidisciplinary treatment.
    Milas M; Bush RL; Lin P; Brown K; Mackay G; Lumsden A; Weber C; Dodson TF
    J Vasc Surg; 2003 Mar; 37(3):501-7. PubMed ID: 12618682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calciphylaxis: Approach to Diagnosis and Management.
    Seethapathy H; Noureddine L
    Adv Chronic Kidney Dis; 2019 Nov; 26(6):484-490. PubMed ID: 31831126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis.
    Brucculeri M; Cheigh J; Bauer G; Serur D
    Semin Dial; 2005; 18(5):431-4. PubMed ID: 16191185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical cannabis-based medicines - A novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: An open label trial.
    Maida V; Shi RB; Fazzari FGT; Zomparelli L
    Int Wound J; 2020 Oct; 17(5):1508-1516. PubMed ID: 32875692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of calciphylaxis with pamidronate.
    Hooman N; Naghshi-Zadiyan R; Mehrazma M; Jahangiri F
    Iran J Kidney Dis; 2015 Jan; 9(1):67-70. PubMed ID: 25599740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry.
    Brandenburg VM; Kramann R; Rothe H; Kaesler N; Korbiel J; Specht P; Schmitz S; Krüger T; Floege J; Ketteler M
    Nephrol Dial Transplant; 2017 Jan; 32(1):126-132. PubMed ID: 26908770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.